RxDoctor Payments Data

Avikshitha Sudhakara, MD

Internal Medicine · Detroit, MINPI 1679937189

Payments from drug & device makers

$9,366in general payments, 2019–2025

Across 462 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • GSK$929
  • Lilly USA, LLC$711
  • Johnson & Johnson$660
  • AbbVie$488
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$9,366100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,366 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$32,337
Medicare patients
66
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$35,689
EntrestoSacubitril/Valsartan39$13,224
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,910
XareltoRivaroxaban14$6,909
FarxigaDapagliflozin Propanediol11$3,018
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,578
Atorvastatin Calcium125$1,402
Gabapentin102$1,003
Pantoprazole Sodium53$932
Tamsulosin Hcl46$668
Levothyroxine Sodium71$603
Baclofen21$597
Colestipol Hcl11$534
Albuterol Sulfate HfaAlbuterol Sulfate14$515
Bumetanide30$502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$180$35,689105 claims
NovartisEntresto$111$13,22439 claims
GSKTrelegy Ellipta$929$9,91011 claims
Johnson & JohnsonXarelto$660$6,90914 claims
AstraZenecaFarxiga$1,169$3,01811 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$148$22113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →